{
    "name": "albendazole",
    "comment": "Rx",
    "other_names": [
        "Albenza"
    ],
    "classes": [
        "Anthelmintics"
    ],
    "source": "https://reference.medscape.com/drug/albenza-albendazole-342648",
    "pregnancy": {
        "common": [
            "Based on findings from animal reproduction studies, the drug may cause fetal harm when administered to a pregnant woman; however, available human data from a small number of published case series and reports on use of multiple-dose in the first trimester of pregnancy, and several published studies on single-dose use later in pregnancy, have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes",
            "Pregnancy testing recommended for females of reproductive potential prior to initiating therapy"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females: May cause fetal harm when administered to a pregnant woman; advise females of reproductive potential to use effective contraception during treatment and for 3 days after final dose"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "In animal reproductive studies, oral administration of albendazole during period of organogenesis caused embryotoxicity and skeletal malformations in pregnant rats (at doses of 0.10 times and 0.32 times the maximum recommended human dose based on body surface area in mg/m",
                    ") and pregnant rabbits (at doses of 0.60 times the maximum recommended human dose based on body surface area in mg/m",
                    "); drug was also associated with maternal toxicity in rabbits (at doses of 0.60 times recommended human dose based on body surface area in mg/m",
                    "); advise a pregnant woman of potential risk to fetus"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Concentrations of drug and active metabolite, albendazole sulfoxide, reported to be low in human breast milk; there are no reports of adverse effects on breastfed infant and no information on effects on milk production",
            "Developmental and health benefits of breastfeeding should be considered along with motherâ€™s clinical need nd any potential adverse effects on breastfed infant from drug or from underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to albendazole or benzimidazoles"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Monitor theophylline levels if used concomitantly",
                "Potential for bone marrow suppression, aplastic anemia & agranulocytosis; monitor blood counts in all patients at the beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy; discontinue therapy if clinically significant changes in blood counts occur",
                "Pre-existing neurocysticercosis may be uncovered in patients treated w/ albendazole for other conditions, apparent by neurological symptoms (eg, seizures, increased intracranial pressure, focal signs); promptly treat w/ corticosteroid & anticonvulsant therapy",
                "Obtain pregnancy test in women of reproductive potential prior to therapy and avoid usage in pregnant women except in clinical circumstances where no alternative management is appropriate; discontinue therapy if pregnancy occurs and apprise patient of potential hazard to fetus",
                "Risk of retinal damage in retinal cysticercosis; cases of retinal involvement reported; examine patient for presence of retinal lesions before initiating therapy for neurocysticercosis",
                "Reversible elevations of liver enzymes may occur; monitor liver enzymes before start of each treatment cycle and at least every 2 weeks while on therapy and discontinue if clinically significant elevations occur; patients with abnormal LFTs and hepatic echinococcosis are at increased risk of hepatotoxicity; discontinue therapy if LFT elevations >2 times upper limit of normal; may consider restarting treatment when LFT values return to pretreatment levels"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, albendazole.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "acalabrutinib, albendazole.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may increase risk of myelosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin decreases levels of albendazole by increasing metabolism. Use Caution/Monitor. Fosphenytoin decreases levels of albendazole active metabolites; monitor for decreased efficacy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of albendazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin decreases levels of albendazole by increasing metabolism. Use Caution/Monitor. Phenytoin decreases levels of albendazole active metabolites; monitor for decreased efficacy."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "dexamethasone increases levels of albendazole by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "praziquantel",
            "description": {
                "common": "praziquantel increases levels of albendazole by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Neurocysticercosis",
            "percent": "11"
        },
        {
            "name": "Hydatid disease",
            "percent": "1.3"
        },
        {
            "name": "Hydatid disease",
            "percent": "15.6"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "1"
        },
        {
            "name": "Hydatid disease",
            "percent": "6"
        },
        {
            "name": "Hydatid disease",
            "percent": "3.7"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "6.2"
        },
        {
            "name": "Hydatid disease",
            "percent": "1.2"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "1"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "1"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "1"
        },
        {
            "name": "Hydatid disease",
            "percent": "1.6"
        },
        {
            "name": "Neurocysticercosis",
            "percent": "1"
        },
        {
            "name": "Hydatid disease",
            "percent": "1"
        }
    ]
}